Amphotericin B conjugated stabilized gold nanoparticles and uses thereof
Inventors
Ghosh, Chandradhish • Seeberger, Peter
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Conjugates of amphotericin B and gold nanoparticles stabilized with thiohexoses or thiopentoses, and a method to produce said nanoparticles are described. As the conjugates of amphotericin B to the stabilized gold nanoparticles show several advantages over amphotericin B alone, pharmaceutical compositions comprising said nanoparticles, and to their use for treat fungal and leishmanial infection are described. These amphotericin B stabilized gold nanoparticles are dispersible in water and are not toxic for mammalian cells differently from free amphotericin B and other currently used amphotericin B preparations. Importantly, the conjugates of amphotericin B and stabilized gold nanoparticles are more efficacious in treating all forms of Cryptococcal infections (planktonic, intracellular and biofilms) than amphotericin B.
Core Innovation
The invention relates to amphotericin B conjugated gold nanoparticles comprising a gold nanoparticle core having a surface connected to thiohexuronic acid or thiopenturonic acid molecules that stabilize the gold nanoparticle core. At least one amphotericin B molecule is present on the nanoparticle, with one amphotericin B molecule covalently bound to one of the thiohexuronic acid or thiopenturonic acid molecules through the amino group of amphotericin B and the carboxylic acid group of the thiohexuronic acid or thiopenturonic acid molecule.
The amphotericin B conjugated gold nanoparticles are produced by reduction of aurochloric acid in the presence of thiohexuronic acid or thiopenturonic acid, and the resulting nanoparticles are water dispersible. A required particle size range is comprised between 5 nm and 12 nm, and the amphotericin B molecule is covalently connected through the thiohexuronic or thiopenturonic acid surface ligands rather than only physically associated.
The described subject matter also frames therapeutic use for treating fungal infection and leishmania infection. Therapeutic administration is described using therapeutically effective amounts of the amphotericin B conjugated gold nanoparticles, and the documented outcomes include reduction of infection after administering the nanoparticles.
Claims Coverage
The independent claim covers amphotericin B conjugated gold nanoparticles with at least five inventive features: a thiohexuronic acid or thiopenturonic acid surface stabilizer, a defined covalent amino-to-carboxy linkage to amphotericin B, production by reducing aurochloric acid in the presence of the selected thioacid, water dispersibility, and a particle size range from 5 nm to 12 nm.
Thiohexuronic acid or thiopenturonic acid stabilized gold nanoparticle core with amphotericin B covalently linked via amino-to-carboxy
Amphotericin B conjugated gold nanoparticles comprising a gold nanoparticle core with thiohexuronic acid or thiopenturonic acid molecules connected to the surface to stabilize the gold nanoparticle core, and at least one amphotericin B molecule covalently bound to one of the thiohexuronic acid or thiopenturonic acid molecules via the amino group of amphotericin B and the carboxylic acid group of the thiohexuronic acid or thiopenturonic acid molecule.
Produced by reduction of aurochloric acid in presence of thiohexuronic acid or thiopenturonic acid
The amphotericin B conjugated gold nanoparticles are produced by reduction of aurochloric acid in presence of thiohexuronic acid or thiopenturonic acid.
Water dispersible amphotericin B conjugated gold nanoparticles with 5 nm to 12 nm particle size range
The amphotericin B conjugated gold nanoparticles are water dispersible and have a particle size range comprised between 5 nm and 12 nm.
Overall, the claim coverage is centered on a defined amphotericin B-thiohexuronic or thiopenturonic acid covalently linked gold nanoparticle architecture, with production tied to reduction of aurochloric acid in the presence of the stabilizing thioacid, and with explicit constraints of water dispersibility and particle size from 5 nm to 12 nm.
Stated Advantages
Improved solubility compared to free amphotericin B.
Reduced mammalian toxicity, including reduced RBC/macrophage toxicity.
Increased antifungal activity, including against Cryptococcus.
Increased antileishmanial activity, including against Leishmania.
Activity against Cryptococcus and Leishmania extracellular, intracellular, and biofilm forms.
Documented Applications
Therapeutic use for fungal infections, including infections involving Cryptococcus and other fungi mentioned in the document.
Therapeutic use for leishmanial infections, including extracellular, intracellular, and biofilm forms.
Pharmaceutical composition use, including compositions comprising amphotericin B conjugated gold nanoparticles with a pharmaceutically acceptable vehicle/excipient/diluent and optional second drug selected from flucytosine, fluconazole, or paromomycin.
Interested in licensing this patent?